Business
Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco
Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Dec. 31, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Dec. 31, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference.\n\n \n \n\n \nThe company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th. \nMr. Barad will provide an overview on the company's mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.\nCannabics Pharmaceuticals proprietary IP, alongside its drug discovery platform and AI predictive capabilities, is based on a personalized approach to treat cancer and its side effects. The company's goals are to leverage its technology and look at new partnerships when meeting with some of these Life Sciences companies. \nAbout Cannabics Pharmaceuticals\nHeadquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Face...